COMMUNIQUÉS West-GlobeNewswire
-
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
03/02/2026 -
Vivos Inc Updates Human Therapy Progress in India
03/02/2026 -
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
03/02/2026 -
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026 -
Ardelyx Receives New Patent for Tenapanor
03/02/2026 -
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
03/02/2026 -
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
03/02/2026 -
Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Appointed to the Florida Board of Pharmacy by Governor Ron DeSantis
03/02/2026 -
Caring Brands Secures Two New U.S. Patents Strengthening Hair Enzyme Booster Technology
03/02/2026 -
Department of Education Proposal Still Excludes Nursing from “Professional Degree” Definition
03/02/2026 -
MedRisk Acquires Horizon Casualty Services
03/02/2026 -
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
03/02/2026 -
Clever Care Health Plan Increases Enrollment by Nearly 50 Percent in 2026 Medicare Annual Enrollment Period
03/02/2026 -
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026 -
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026 -
Mesa Labs Announces Third Quarter Results
03/02/2026 -
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
03/02/2026 -
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
03/02/2026 -
Byonyks X1: Revolutinizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
Pages